Summary

ASEAN Rabies Veterinary Vaccines Market Growth & Trends

The ASEAN rabies veterinary vaccines market size is expected to reach USD 46.41 million in 2030 and is projected to grow at a CAGR of 6.73% from 2025 to 2030. The market is primarily driven by growing rabies vaccination coverage among dogs in ASEAN countries, rising awareness regarding zoonotic diseases, and increasing government initiatives to eradicate animal and human rabies by the end of 2030.

Appropriate management of the disease in domestic dog populations is essential for the prevention of rabies in humans. The majority of documented rabies cases in both animals and humans of ASEAN countries are caused by dogs. To effectively prevent and control both animal and human rabies, it is vital to raise public awareness regarding the disease while also encouraging responsible pet ownership and animal welfare. Technical and socio-cultural frameworks should both be taken into consideration in a rabies control program. Technical aspects consist of dog population management, vaccination programs, adequate diagnostic capability, disease surveillance programs, and animal movement control. The socio-cultural factors include educating the public and advocating ethical pet ownership and animal welfare.

A framework for collaboration between the FAO, OIE, WHO, and the Global Alliance for Rabies Control (GARC) called "United Against Rabies" has been established for achieving "Zero human rabies deaths by 2030." Along with continuing to urge for stronger actions and involvement in the "United Against Rabies" initiative, ASEAN member states will continue to collaborate with the other partners to prevent human deaths caused by dog-mediated rabies. Several ASEAN member states are facing challenges in achieving the goal set by The ASEAN Rabies Elimination Strategy (ARES) to eradicate rabies. In most ASEAN countries, rabies is still widespread among dogs and rabid dog bites are responsible for almost all human instances of the disease in the region. Vaccination in dogs is considered to be the most affordable method of preventing human rabies.

In ASEAN countries, rabies is a serious public health concern. It has significant adverse effects on human health, the economy, and animal welfare. The primary reservoir and transmitter of rabies in the region are domestic dogs. Lack of funding, a lack of political commitment to rabies control initiatives, a lack of agreement on a strategy, weak intersectoral coordination, insensitive surveillance systems, an inadequate management structure, limited access to modern rabies vaccines, supply issues, a lack of public awareness and cooperation, myths, and religious concerns are all key challenges to rabies control programs. Most ASEAN nations have an endemic canine rabies issue. However, widespread immunization can reduce disease in dog population. The majority of policy and decision-making is done at the national level, therefore developing, and implementing rabies management policies can benefit from a thorough understanding of the costs associated with preventative and control measures with adequate vaccine supply.

ASEAN Rabies Veterinary Vaccines Market Report Highlights

• Companion animals accounted for the largest revenue share of over 95.0% in 2024 and is anticipated to grow at the fastest CAGR over the forecast period

• The hospital/clinical pharmacy segment accounted for the largest revenue share of over 45.0% in 2024

• The e-commerce segment is anticipated to grow at the fastest CAGR over the forecast period. This growth is attributed to the increasing trend of digital platforms and their adoption among people due to their convenience

• The Thailand market is anticipated to grow at a significant CAGR over the forecast period

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. GVR’s Internal Database
1.3.3. Secondary Sources
1.3.4. Primary Research
1.4. Information/Data Analysis
1.5. Market Formulation & Visualization
1.6. Data Validation & Publishing
1.7. Model Details
1.7.1. Commodity flow analysis
1.7.2. ASEAN Market: CAGR Calculation
1.8. List of Secondary Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Rabies Veterinary Vaccines Industry Outlook
3.1. Market Lineage Outlook
3.1.1. Parent Market
3.1.2. Ancillary Market
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising zoonosis concerns
3.2.1.2. Government initiatives
3.2.1.3. Technological Advancements
3.2.2. Market Restraint Analysis
3.2.2.1. Limited access to veterinary services in under developed countries
3.2.3. Market Opportunity Analysis
3.2.4. Market Challenge Analysis
3.3. Rabies Veterinary Vaccines Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitution
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political & Legal landscape
3.3.2.2. Economic and Social landscape
3.3.2.3. Technological landscape
3.3.2.4. Environmental landscape
3.3.3. Regulatory Framework
3.3.4. Product Pricing Analysis
3.3.5. Estimated Animal Population, by key species, 2024
3.3.6. COVID-19 Impact Analysis
Chapter 4. Rabies Veterinary Vaccines Market: Application Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. ASEAN Rabies Veterinary Vaccines Market: Application Movement Analysis
4.3. ASEAN Rabies Veterinary Vaccines Market Size & Trend Analysis, by application, 2018 to 2030 (USD Million)
4.3.1. Companion Animals
4.3.1.1. Companion Animals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2. Livestock Animals
4.3.2.1. Livestock Animals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Rabies Veterinary Vaccines Market: Distribution Channel Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. ASEAN Rabies Veterinary Vaccines Market: Distribution Channel Movement Analysis
5.3. ASEAN Rabies Veterinary Vaccines Market Size & Trend Analysis, by distribution channel, 2018 to 2030 (USD Million)
5.3.1. Retail
5.3.1.1. Retail Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.2. E-Commerce
5.3.2.1. E-Commerce Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.3. Hospital/Clinical Pharmacy
5.3.3.1. Hospital/Clinical Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Rabies Veterinary Vaccines Market: Country Estimates & Trend Analysis
6.1. Country Dashboard
6.2. Rabies Veterinary Vaccines Market Share, By Country, 2024 & 2030, USD Million
6.3. Country Outlook
6.4. Indonesia
6.4.1. Indonesia Rabies Veterinary Vaccines Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.2. Vietnam
6.4.2.1. Vietnam Rabies Veterinary Vaccines Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.3. Myanmar
6.4.3.1. Myanmar Rabies Veterinary Vaccines Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.4. Malaysia
6.4.4.1. Malaysia Rabies Veterinary Vaccines Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.5. Thailand
6.4.5.1. Thailand Rabies Veterinary Vaccines Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.6. Philippines
6.4.6.1. Philippines Rabies Veterinary Vaccines Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.7. Laos
6.4.7.1. Laos Rabies Veterinary Vaccines Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.8. Cambodia
6.4.8.1. Cambodia Rabies Veterinary Vaccines Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.9. Rest of ASEAN
6.4.9.1. Rest of ASEAN Rabies Veterinary Vaccines Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Market Participant Categorization
7.2. Company Market Position Analysis/ Heap Map Analysis
7.3. Company Profiles
7.3.1. Boehringer Ingelheim International GmbH
7.3.1.1. Participant’s Overview
7.3.1.2. Financial Performance
7.3.1.3. Product Benchmarking
7.3.1.4. Strategic Initiatives
7.3.2. Zoetis
7.3.2.1. Participant’s Overview
7.3.2.2. Financial Performance
7.3.2.3. Product Benchmarking
7.3.2.4. Strategic Initiatives
7.3.3. Merck & Co., Inc.
7.3.3.1. Participant’s Overview
7.3.3.2. Financial Performance
7.3.3.3. Product Benchmarking
7.3.3.4. Strategic Initiatives
7.3.4. Virbac
7.3.4.1. Participant’s Overview
7.3.4.2. Financial Performance
7.3.4.3. Product Benchmarking
7.3.4.4. Strategic Initiatives
7.3.5. Indian Immunologicals Ltd.
7.3.5.1. Participant’s Overview
7.3.5.2. Financial Performance
7.3.5.3. Product Benchmarking
7.3.5.4. Strategic Initiatives
7.3.6. BroadChem Philippines Biopharma Corporation.
7.3.6.1. Participant’s Overview
7.3.6.2. Financial Performance
7.3.6.3. Product Benchmarking
7.3.6.4. Strategic Initiatives
7.4. Strategy Mapping
7.4.1. Mergers & Acquisitions
7.4.2. Partnerships & Collaborations
7.4.3. Expansions
7.4.4. Others